B7-H3在食管癌中的研究进展

朱昱霖; 易忠权; 宋建祥

引用本文:

【打印本页】【下载PDF全文】【查看/发表评论】【下载PDF阅读器】【关闭】

←前一篇|后一篇→

过刊浏览高级检索

本文已被：浏览 115次下载 39次	码上扫一扫！
分享到：微信更多字体:加大+\|默认\|缩小-
B7-H3在食管癌中的研究进展
朱昱霖^1,2, 易忠权³, 宋建祥^1,2
1.南通大学第六附属医院(盐城市第三人民医院)心胸外科, 盐城 224000;2.南通大学医学院, 南通 226000;3.南通大学第六附属医院(盐城市第三人民医院)中心实验室, 盐城 224000

摘要:

食管癌是一种高发恶性肿瘤，发病率逐年上升，常规手术治疗及放化疗疗效较差。近年来，免疫疗法的不断发展为食管癌的治疗提供了新思路。B7-H3（CD276）在食管癌等多种类型的肿瘤中过表达，与患者的不良预后密切相关，是一种有前景的免疫治疗靶点。B7-H3对食管癌免疫反应主要发挥负性调节作用，可能是食管癌潜在的生物标志物，有望为肿瘤免疫治疗拓展新方向。本文对B7-H3在食管癌中作用的研究进展作一综述。

关键词: 食管癌 B7-H3 免疫分子标志物

DOI：10.12025/j.issn.1008-6358.2023.20220243

分类号:

基金项目:江苏省第十五批“六大人才高峰”资助项目(WSW-282).

Research progress of B7-H3 in esophageal cancer

ZHU Yu-lin^1,2, YI Zhong-quan³, SONG Jian-xiang^1,2

1.Department of Cardiothoracic Surgery, the Sixth Affiliated Hospital of Nantong University (Yancheng Third People's Hospital), Yancheng 224000, Jiangsu, China;2.Nantong Universty Medical School, Nantong 226000, Jiangsu, China;3.Department of Central Laboratory, the Sixth Affiliated Hospital of Nantong University (Yancheng Third People's Hospital), Yancheng 224000, Jiangsu, China

Abstract:

Esophageal cancer is a high-incidence malignant tumor, and its incidence is increasing year by year. Conventional surgical treatment, radiotherapy and chemotherapy have no enough improvement in the poor prognosis. In recent years, the continuous development of immunotherapy has provided new ideas for the treatment of esophageal cancer. B7-H3 (CD276), is overexpressed in various types of tumors such as esophageal cancer, has been confirmed to be closely related to the poor prognosis of patients, and may be a promising immunotherapy target. B7-H3 mainly plays a negative regulatory role in esophageal cancer immune response. B7-H3 may be a potential biomarker in tumorigenesis and the development of esophageal cancer, which is expected to expand new directions for anti-tumor immunotherapy. This article reviews research progress of the roles of B7-H3 in esophageal cancer.

Key words: esophageal cancer B7-H3 immunity biomarkers